To describe recent evidence from the literature pertaining to juvenile idiopathic arthritis (JIA)-associated uveitis.
Introduction
Uveitis is observed in 30% of antinuclear antibody (ANA)-positive patients with juvenile idiopathic arthritis (JIA) [1] and is an important cause of ocular morbidity in childhood and beyond. The use of immunosuppressive therapy has greatly reduced the ocular complications from JIA-associated uveitis [2] . Tight perioperative control of intraocular inflammation has also enabled successful cataract surgery to be performed, with implantation of intraocular lenses. Although biologic agents hold promise in the treatment of JIA-associated uveitis, their long-term safety profile is yet to be established.
Juvenile idiopathic arthritis: epidemiology and pathogenesis
JIA is a collection of heterogeneous chronic childhood arthritides with onset before 16 years of age and persisting 6 weeks or longer with likely distinct pathophysiologic mechanisms that lead to a common pattern of tissue destruction [3] . There are four subtypes of JIA: persistent oligoarticular (four or less joints involved throughout course of disease), extended oligoarticular (four or less joints involved during first 6 months and five or more joints involved thereafter), rheumatoid factor-positive polyarticular and rheumatoid factor-negative polyarticular. The incidence of JIA in the USA and Canada is estimated at 0.041-0.061 per 1000 children [3] . Thirty to 60% of all JIA in the USA and Europe is oligoarticular, which has a peak onset of 2-4 years of age, whereas polyarticular JIA has a bimodal onset, the first at 1-4 years of age and the second at 6-12 years. The female : male ratio in oligoarticular JIA is 3 : 1 [3] .
Susceptibility to JIA is inherited; siblings of patients with JIA have a 15-30-fold higher risk of developing JIA compared with the general population. Evidence suggests that JIA is largely a T-cell-mediated disease. Dysregulation of cytokines, especially tumor necrosis factor (TNF), contributes to the cause in both oligoarticular and polyarticular JIA. Environmental triggers are hypothesized, but remain unsubstantiated [3] .
Ocular manifestations of juvenile idiopathic arthritis
A large, population-based study of JIA patients in Germany found a 12% prevalence of uveitis in all types of JIA, including 25% in oligoarticular-extended and 16% in oligoarticular-persistent [4] . The mean age of uveitis presentation was 5.2 years. Eighty-three percent of patients with uveitis had anterior uveitis, followed by 9% with intermediate uveitis, 1% posterior uveitis and 7% panuveitis. Seventy percent of uveitis patients had bilateral involvement. Predictors of complications were presence of complications at first visit and presentation of uveitis before arthritis, but not ANA positivity.
Retrospective series have reported that 28-67% of patients with JIA-associated uveitis develop ocular complications [5, 6] . In one series, 12% had a poor visual outcome [5] and in another, 36% of affected eyes had 20/50 or worse visual acuity and 24% had 20/200 or worse visual acuity at presentation [6] . The main causes of poor vision were cataract, band keratopathy and glaucoma [6] . Active intraocular inflammation (0.5þ cells) was associated with increased risk of visual impairment and blindness.
A recent retrospective review by Saurenmann et al. [7] found the rate of uveitis was significantly higher in girls aged 1-2 years (37%) than in boys (7%) in the same age group. The same relationship held true in ANA-positive patients aged 1-2 years, with 47% of girls and 10% of boys having uveitis. The rate decreased to less than 10% in girls with the onset of JIA above 7 years of age. In a recent retrospective review of 117 eyes (65 patients), male sex was independently associated with need for cataract surgery, cystoid macular edema and papillitis and had significantly more of these features at 5 years followup [8] Male sex was associated with a 6.61-fold increased odds of blindness [9] .
Thorne et al. [10 ] recently retrospectively examined 75 consecutive patients (132 eyes) with JIA-associated chronic uveitis for the risk of development of cataract. Significant risk factors included presence of posterior synechiae, active uveitis and topical corticosteroid use at presentation. The overall incidence of new-onset cataract over a median follow-up of 4 years was 0.04 per eye-year. The incidence of new cataract was 0 per eye-year among patients receiving less than or equal to two drops of topical corticosteroids per day and 0.16 per eye-year among patients receiving more than three drops daily.
Medical treatment of juvenile idiopathic arthritis and juvenile idiopathic arthritisassociated uveitis
The use of biologic agents in JIA has recently been reviewed [11, 12] . Agents approved by Food and Drug Administration (FDA) for treating JIA are adalimumab [13] and etanercept, both TNF-alpha blockers, and abatacept [14] , a T-cell activation blocker. By 21 months follow-up, 90% of patients taking abatacept experienced more than 30% improvement in JIA, as defined by the American College of Rheumatology Pediatric 30 Criteria [15] . In contrast, a randomized controlled trial of infliximab 3 mg/kg with methotrexate for children with polyarticular JIA did not show a statistically significant difference compared with placebo [16] . The study was instructive in finding that the 6 mg/kg dose may be well tolerated in children than the 3 mg/kg dose, with fewer serious adverse events, infusion reactions and development of antibodies. At 4 years of follow-up, 44% achieved improvement of more than 30% in JIA [17] .
Corticosteroids remain the mainstay of initial treatment for uveitis. For patients requiring chronic therapy, the initial agents of choice are typically antimetabolites including methotrexate, mycophenolate mofetil and azathioprine. Cyclosporine has limited value in the treatment of JIA-associated uveitis [18] . In cases of refractory inflammation, biologic agents are used, usually in conjunction with an antimetabolite. There are no prospective controlled studies on the use of immunosuppressive medications in children with uveitis. An excellent comprehensive review of the current medical treatment of uveitis in children has recently been published [19] . Use of immunosuppressive therapy has been shown, in a retrospective study, to be associated with a 74% reduction in the development of hypotony (P ¼ 0. There have also been case series on other biologic drugs and JIA-associated uveitis. Abatacept has been reported to control refractory uveitis in a girl with psoriatic arthritis and immunoglobulin A (IgA) deficiency [21] . A case series reported remission of refractory JIA-associated uveitis in six of seven patients taking abatacept after a mean of 9.2 months of treatment [22] . Other biologic agents in investigation include interleukin (IL)-1 antagonists such as anakinra and the IL-6 antagonist tocilizumab [12] . High-dose daclizumab, a humanized monoclonal antibody against IL-2 receptor, has been reported to provide a two-step reduction in anterior chamber cells in four of six children with JIA-associated uveitis [23] . However, the manufacturer of daclizumab discontinued production in the USA in September 2009, citing declining market demand.
As more patients receive immunosuppressive therapy for ocular inflammatory disease, the long-term safety profile of these treatments becomes important, particularly in children with JIA, who may require systemic treatment for decades. A meta-analysis of clinical trials in which patients with adult rheumatoid arthritis randomized to TNF-alpha inhibitors with 22-54-week follow-up found a 3.3-fold increase in the risk of cancer [24] . A recent large-scale retrospective cohort study by Kempen et al. [25 ] included 7957 US residents with noninfectious ocular inflammatory disease of whom 2340 received immunosuppressive therapy. Patients who took antimetabolites, T-cell inhibitors and corticosteroids had overall and cancer-related mortality similar to patients who never took immunosuppressive medications and similar to the general US population. Patients who took TNF-alpha inhibitors had increased overall and cancer-related mortality. Even though this result raises concern for the safety of TNF inhibitors, the sample size and person-year follow-up of the TNF group was only a fraction of the total study population, reflecting the study enrollment end date in 2005. The US FDA has issued a black box warning on the increased risk of cancer, particularly lymphoma, in children and adolescents taking TNFalpha inhibitors. (www.fda.gov/NewsEvents, cancer warnings required for TNF blockers, 4 August 2009). Even though there was no mention of patients with uveitis, the warning still raises serious concerns.
Surgical management of juvenile idiopathic arthritis-associated uveitis
Successful surgical intervention in the setting of chronic uveitis requires careful planning for optimal results.
Cataract surgery
Cataract surgery in the setting of uveitis has recently been well reviewed [26, 27] . Historically, authorities have cautioned against primary placement of intraocular lens (IOLs) in patients with JIA because of the risk of secondary cyclitic membranes and development of hypotony [28] [29] [30] . With more widespread practice of strict control of uveitis, at least 3 months prior to surgery and using systemic immunomodulatory therapy, good postoperative results can be achieved [31] . Even so, the presence of an IOL can still incite recalcitrant inflammation, necessitating removal of the implant [32] . Alternatively, pars plana lensectomy with anterior vitrectomy and subsequent aphakia can be an effective way to manage uveitic cataract [33] . Pars plana vitrectomy (PPV) in combination with phacoemulsification has been reported to successfully improve vision in adults and children with chronic uveitis [34] [35] [36] .
A recent retrospective study by Sijssens et al. [37 ] examined long-term complications after cataract surgery in aphakic and pseudophakic eyes of children with JIAassociated uveitis. Intraocular inflammation was under 'maximal control' for a minimum of 3 months prior to surgery. There was no difference in perioperative corticosteroid management between the two groups. Nineteen aphakic eyes and 29 pseudophakic eyes (of which five had polymethylmethacrylate IOLs and 24 had acrylic) were included in the study. There was no statistically significant difference in complications between the two groups. Cystoid macular edema was higher in the aphakic group, but did not achieve statistical significance. Visual acuity was significantly better in pseudophakic eyes than in aphakic eyes up to 7 years after cataract extraction. The findings suggest that IOLs in children with JIA-associated uveitis are neither a risk factor nor protective of development of secondary inflammatory glaucoma. The authors offered the following relative contraindications for IOL placement: age less than 4 years, hypotony, fellow eye IOL-related complication and shallow anterior chamber.
Fluocinolone acetonide implant
The intravitreal fluocinolone acetonide implant was approved in 2005 for chronic noninfectious uveitis affecting the posterior segment (posterior, intermediate and panuveitis). The use of the implant in children and particularly in children with JIA-associated uveitis has not been reported, as the majority of intraocular inflammation in JIA is anterior uveitis. A dose-randomized, historically controlled multicenter trial of the fluocinolone acetonide implant for patients with recurrent noninfectious posterior uveitis included patients 6 years or older, but there was no mention specifically of children as a subgroup [38, 39] . The Multicenter Uveitis Steroid Treatment Trial (MUST) is a randomized double-masked trial comparing the fluocinolone acetonide implant and conventional medical therapy for the treatment of chronic noninfectious uveitis in patients age 13 and over [40] . Five patients (2%) had JIA-associated uveitis. Enrollment is complete and results are expected in 2011.
Pars plana vitrectomy
PPV is variably performed in children with JIA-associated uveitis. It has been advocated historically in recalcitrant chronic uveitis with posterior involvement, prior to widespread use of immunomodulatory medications [41] .
Recently, Giuliari et al. [42] reported on the results of PPV in 28 eyes of 20 patients aged 16 or younger with more than 6 months postoperative follow-up, including five eyes with JIA-associated iridocyclitis. The mean age at time of PPV was 11.2 years. The mean time of followup was 13.5 months. All eyes had active intraocular inflammation with or without medical treatment prior to PPV. Surgery was able to reduce systemic medication for control of uveitis. Ninety-six percent of patients had inactive uveitis with or without medical treatment at last postoperative follow-up.
Long-term follow-up of patients with juvenile idiopathic arthritis
The ocular morbidity of JIA-associated uveitis continues well into adulthood. Recently, Skarin et al. [43] reported on the 24-year follow-up of a cohort of 55 consecutive patients and found that 49% still had active uveitis. Twenty-two percent had uveitic glaucoma and 51% had cataract at 24year follow-up. In another study, 26.7% of patients having JIA-associated uveitis for more than 15 years duration had a visual acuity of 6/12 or worse [44] .
Discontinuing medical treatment
With better methods of achieving control of both uveitis and arthritis in patients with JIA, coupled with concerns about the long-term safety profile of immunosuppressive agents, the issue of if and when to stop medical treatment has now become increasingly relevant. The general expert opinion among uveitis specialists is to try to taper immunomodulatory therapy after 12-24 months of quiescence of uveitis. Currently, however, there are no studies in the ophthalmic literature addressing when to withdraw treatment. Recently, Foell et al. [45] , for the Pediatric Rheumatology International Trials Organization (PRINTO), conducted a prospective, open, multicenter and multinational clinical trial on 364 patients with JIA, randomized to withdrawal of methotrexate at either 6 or 12 months after confirmed clinical remission of JIA (including no active uveitis) while on medical treatment (maximum dose 15 mg/m 2 per week). The relapse rate within 24 months of study enrollment was 56.7% in the 6month group and 55.6% in the 12-month group. The median time to relapse was 21.0 months in the 6-month group and 23.0 months in the 12-month group. As JIA joint disease and JIA-associated uveitis follow different disease courses, this study offers little guidance in the timing of withdrawal of medical treatment in JIA-associated uveitis. Further study is needed in this area.
Conclusion
JIA remains a challenging disease to treat, with ocular morbidity lasting well into adulthood. Randomized con-trolled trials are needed to assess the efficacy of antimetabolites, as these remain the first-line treatment for chronic JIA-associated uveitis. Long-term safety of biologic treatment is a concern, especially as children with JIA require years of treatment.
